Cymbal Michael, Naseem Zehra, Hoxha Din, Garg Samita
Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
ACG Case Rep J. 2025 Aug 4;12(8):e01789. doi: 10.14309/crj.0000000000001789. eCollection 2025 Aug.
This retrospective case series investigates the impact of GLP-1 receptor agonists (GLP-1RAs) on whole-gut gastrointestinal motility using wireless motility capsule testing. We analyzed 10 patients on GLP-1RAs who underwent wireless motility capsule testing for constipation or gastroparesis to assess gastric, small bowel, and colonic transit times. Delayed gastric emptying time was observed in 80% of patients, whereas delayed whole-gut transit time was noted in 44% of patients. The 3 patients on semaglutide (1 mg) had the longest gastric emptying time, delayed whole-gut transit time, and were the only patients with delayed small bowel transit time. Although limited by retrospective observation, our findings are consistent with the effects of GLP-1RAs on gastric motility delay and suggest an impact on whole-gut motility. With the expanding use of GLP-1RAs, these findings underscore the need for prospective studies using emerging motility technologies to further characterize the motility effects both during treatment and after cessation, thereby guiding evidence-based clinical decision-making.
本回顾性病例系列研究使用无线动力胶囊测试，探究胰高血糖素样肽-1受体激动剂（GLP-1RAs）对全肠道胃肠动力的影响。我们分析了10例接受GLP-1RAs治疗的患者，这些患者因便秘或胃轻瘫接受了无线动力胶囊测试，以评估胃、小肠和结肠的转运时间。80%的患者观察到胃排空延迟，而44%的患者全肠道转运时间延迟。3例使用司美格鲁肽（1毫克）的患者胃排空时间最长，全肠道转运时间延迟，且是仅有的小肠转运时间延迟的患者。尽管本研究受回顾性观察的限制，但我们的研究结果与GLP-1RAs对胃动力延迟的作用一致，并提示其对全肠道动力有影响。随着GLP-1RAs的使用不断增加，这些研究结果强调需要采用新兴动力技术进行前瞻性研究，以进一步明确治疗期间和停药后的动力效应，从而指导基于证据的临床决策。
